258 related articles for article (PubMed ID: 35653814)
1. Genetic therapeutic advancements for Dravet Syndrome.
Chilcott E; Díaz JA; Bertram C; Berti M; Karda R
Epilepsy Behav; 2022 Jul; 132():108741. PubMed ID: 35653814
[TBL] [Abstract][Full Text] [Related]
2. Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome.
Lersch R; Jannadi R; Grosse L; Wagner M; Schneider MF; von Stülpnagel C; Heinen F; Potschka H; Borggraefe I
Neuroscientist; 2023 Dec; 29(6):732-750. PubMed ID: 35414300
[TBL] [Abstract][Full Text] [Related]
3. Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies.
Mei D; Cetica V; Marini C; Guerrini R
Epilepsia; 2019 Dec; 60 Suppl 3():S2-S7. PubMed ID: 31904125
[TBL] [Abstract][Full Text] [Related]
4. Myoclonic Absence Seizures in Dravet Syndrome.
Myers KA; Scheffer IE
Pediatr Neurol; 2017 May; 70():67-69. PubMed ID: 28233668
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and comorbidities of SCN1A-related seizure disorders.
de Lange IM; Gunning B; Sonsma ACM; van Gemert L; van Kempen M; Verbeek NE; Sinoo C; Nicolai J; Knoers NVAM; Koeleman BPC; Brilstra EH
Epilepsy Behav; 2019 Jan; 90():252-259. PubMed ID: 30527252
[TBL] [Abstract][Full Text] [Related]
6. Genetics and gene therapy in Dravet syndrome.
Higurashi N; Broccoli V; Hirose S
Epilepsy Behav; 2022 Jun; 131(Pt B):108043. PubMed ID: 34053869
[TBL] [Abstract][Full Text] [Related]
7. A novel variant in SCN1A gene associated with Dravet syndrome.
Pathirana B; Hettiarachchi D; Neththikumara NF; Ratnayake PD; Dissanayake V
Seizure; 2019 Jul; 69():213-214. PubMed ID: 31102827
[No Abstract] [Full Text] [Related]
8. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
[TBL] [Abstract][Full Text] [Related]
9. Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K).
Beretta S; Gritti L; Ponzoni L; Scalmani P; Mantegazza M; Sala M; Verpelli C; Sala C
Mol Autism; 2022 Jan; 13(1):1. PubMed ID: 34980259
[TBL] [Abstract][Full Text] [Related]
10. Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome.
Niibori Y; Lee SJ; Minassian BA; Hampson DR
Hum Gene Ther; 2020 Mar; 31(5-6):339-351. PubMed ID: 31830809
[TBL] [Abstract][Full Text] [Related]
11. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications.
Brunklaus A; Brünger T; Feng T; Fons C; Lehikoinen A; Panagiotakaki E; Vintan MA; Symonds J; Andrew J; Arzimanoglou A; Delima S; Gallois J; Hanrahan D; Lesca G; MacLeod S; Marjanovic D; McTague A; Nuñez-Enamorado N; Perez-Palma E; Scott Perry M; Pysden K; Russ-Hall SJ; Scheffer IE; Sully K; Syrbe S; Vaher U; Velayutham M; Vogt J; Weiss S; Wirrell E; Zuberi SM; Lal D; Møller RS; Mantegazza M; Cestèle S
Brain; 2022 Nov; 145(11):3816-3831. PubMed ID: 35696452
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model.
Yuan Y; Lopez-Santiago L; Denomme N; Chen C; O'Malley HA; Hodges SL; Ji S; Han Z; Christiansen A; Isom LL
Brain; 2024 Apr; 147(4):1231-1246. PubMed ID: 37812817
[TBL] [Abstract][Full Text] [Related]
13. Mapping genetic modifiers of survival in a mouse model of Dravet syndrome.
Miller AR; Hawkins NA; McCollom CE; Kearney JA
Genes Brain Behav; 2014 Feb; 13(2):163-72. PubMed ID: 24152123
[TBL] [Abstract][Full Text] [Related]
14. Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome.
Kwong AK; Fung CW; Chan SY; Wong VC
PLoS One; 2012; 7(7):e41802. PubMed ID: 22848613
[TBL] [Abstract][Full Text] [Related]
15. A Transient Developmental Window of Fast-Spiking Interneuron Dysfunction in a Mouse Model of Dravet Syndrome.
Favero M; Sotuyo NP; Lopez E; Kearney JA; Goldberg EM
J Neurosci; 2018 Sep; 38(36):7912-7927. PubMed ID: 30104343
[TBL] [Abstract][Full Text] [Related]
16. Broadening Neurologic Manifestations in Adult Patients With Dravet Syndrome.
Tsuji S
Neurology; 2022 May; 98(22):913-914. PubMed ID: 35418455
[No Abstract] [Full Text] [Related]
17. Cell-Selective Adeno-Associated Virus-Mediated
Tanenhaus A; Stowe T; Young A; McLaughlin J; Aeran R; Lin IW; Li J; Hosur R; Chen M; Leedy J; Chou T; Pillay S; Vila MC; Kearney JA; Moorhead M; Belle A; Tagliatela S
Hum Gene Ther; 2022 Jun; 33(11-12):579-597. PubMed ID: 35435735
[TBL] [Abstract][Full Text] [Related]
18. Life-span characterization of epilepsy and comorbidities in Dravet syndrome mice carrying a targeted deletion of exon 1 of the Scn1a gene.
Gerbatin RR; Augusto J; Boutouil H; Reschke CR; Henshall DC
Exp Neurol; 2022 Aug; 354():114090. PubMed ID: 35487274
[TBL] [Abstract][Full Text] [Related]
19. Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?
Lim BC; Hwang H; Kim H; Chae JH; Choi J; Kim KJ; Hwang YS; Yum MS; Ko TS
Epilepsy Res; 2015 Jan; 109():34-9. PubMed ID: 25524840
[TBL] [Abstract][Full Text] [Related]
20. Generation of a human iPSC line (UUIGPi015-A) from a patient with Dravet syndrome and a 2.9 Mb deletion spanning SCN1A on chromosome 2.
Schuster J; de Guidi C; Tripathi R; Klar J; Dahl N
Stem Cell Res; 2022 Apr; 60():102712. PubMed ID: 35203050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
